



Cite this: *Chem. Commun.*, 2019, 55, 10784

Received 17th July 2019,
Accepted 14th August 2019

DOI: 10.1039/c9cc05516a

rsc.li/chemcomm

A light-responsive liposomal agent for MRI contrast enhancement and monitoring of cargo delivery†

F. Reeßing,^{ab} M. C. A. Stuart,^{id b} D. F. Samplonius,^c R. A. J. O. Dierckx,^a
B. L. Feringa,^{id ab} W. Helfrich^c and W. Szymanski^{id *ab}

Medical magnetic resonance imaging (MRI) produces high-resolution anatomical images of the human body, but has limited capacity to provide useful molecular information. The light-responsive, liposomal MRI contrast agent described herein could be used to provide an intrinsic theranostic aspect to MRI and enable tracking the distribution and cargo release of drug delivery systems upon light-triggered activation.

In the clinic, Magnetic Resonance Imaging (MRI) is widely used as a non-invasive medical imaging technique that provides anatomical information with excellent resolution, without exposing the patient to ionizing radiation.¹ The contrast in MRI stems from the difference in local densities and relaxation times of protons in tissues. In ~30 million clinical scans performed annually worldwide, the contrast is further enhanced by the administration of paramagnetic contrast agents (CAs), such as gadolinium(III) complexes, which significantly shorten the T_1 relaxation time of surrounding protons.^{2–4} This causes a higher intensity in the T_1 -weighted MR image and enables the visualization of the distribution of the CA in the human body.

Tissue-specific CAs are currently available to image structures that are barely distinguishable on a regular scan, such as the vascularization of the brain.⁵ However, due to the low sensitivity of MRI, the requirement of relatively high (>0.01 mM) local concentrations of CAs for effective signal enhancement presents a major limitation, especially regarding the development of CAs for the imaging of disease-specific biomarkers that are present at much lower concentrations. Therefore – while structures that are highly abundant in the human body, such as fibrin or collagen,

can be readily visualized^{6–10} – targeted imaging of less abundant receptors or other proteins that are associated with certain pathological conditions, remains challenging.

This problem has been previously addressed through the development of responsive CAs, that show increased contrast enhancement upon activation by enzymes, ions, neurotransmitters or that take advantage of changes in *e.g.* pH, temperature or redox potential.^{4,10–16} Even though the effectiveness of this strategy has been proven for these targets, certain limitations to this approach remain: for instance, the untimely and/or off-target activation, as the conditions for the activation of the responsive CAs are frequently also present outside the lesion(s) in normal, healthy tissues.

In this respect, local activation of a CA with light could be used as a general strategy for improved MRI contrast enhancement. Of note, the use of photons as CA activators would not interfere with endogenous physiological processes.¹⁷ Moreover, light can be delivered with high spatiotemporal resolution and is biocompatible within a broad wavelength range.^{18,19} Due to these advantages, the research fields focusing on the use of light for biomedical applications, *e.g.* photopharmacology,²⁰ photodynamic therapy (PDT),²¹ or optogenetics,²² are expanding very quickly fueled by promising results. As compared to other stimuli, such as ultrasound or heat, the use of light also presents specific challenges, including the limited penetration depth and potential toxicity.

The research presented here aims to establish a general strategy for signal amplification in contrast-enhanced MRI, which could be used for selective imaging of low-concentration targets. This strategy envisions the use of targeted light-emitting systems that locally activate the MRI CA, resulting in signal amplification. A key advantage of this approach is that the use of light for activation provides a CA that is readily adaptable to various targets by changing the light-emitting system, in contrast to the systems that are limited to one specific target.

As a key step towards this general goal, we describe here the synthesis and evaluation of a photoactivated MRI CA that changes its relaxivity in response to irradiation with blue light.

^a Department of Radiology, Medical Imaging Center, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713GZ Groningen, The Netherlands. E-mail: w.szymanski@umcg.nl

^b Stratingh Institute for Chemistry, University of Groningen, Nijenborgh 4, 9747 AG Groningen, The Netherlands

^c Translational Surgical Oncology, Department of Surgery, University of Groningen, University Medical Center Groningen, Hanzeplein 1/BA44, 9713GZ Groningen, The Netherlands

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c9cc05516a






Fig. 1 Design principle for light-activated MRI contrast agents for imaging (A) and theranostics (B). The Gd(III)-complex for T_1 -signal enhancement is incorporated into the bilayer of liposomes. Upon irradiation with $\lambda = 400$ nm light, the complex is released, causing a decrease in T_1 relaxivity. (A) A targeting moiety (here an antibody) binding to the target tissue bears a light-emitting system that leads to the release of the gadolinium complex from the lipid bilayer of the liposomes. (B) The liposomal CA can be used for site-selective drug delivery using local irradiation as a stimulus to release the liposome cargo. Upon light irradiation, the liposomes concurrently release the Gd(III) complex and the payload incorporated in their aqueous lumen.

Furthermore, we show how this liposomal CA can simultaneously be used as a responsive cargo delivery system (Fig. 1).²³

For the successful design of a photoactivatable CA, it is crucial to consider the molecular characteristics influencing its relaxivity,²⁴ such as (i) tumbling time, and (ii) number and (iii) residence time of water molecules coordinated to the gadolinium complex.⁸ Control over of the first two features is straightforward and was used for the design of responsive CAs.²⁵ In line with the enzyme-based approach by Aime and co-workers,²⁶ we designed a CA that, upon light-activation, converts from a relatively large nanoscopic complex to a small molecule, resulting in a significant change in relaxivity.

The design relies on linking a gadolinium complex, *via* a photocleavable group, to a lipophilic alkyl chain, which functions as an anchoring group for liposomes (Fig. 2). We hypothesized that irradiation of such liposomes would induce photocleavage and subsequent release of the gadolinium complex with an additional free carboxylic acid group (Fig. 2). This process leads to a lengthening of the T_1 relaxation time. The reasons behind the signal change include the modulation of the tumbling time,




Fig. 2 Molecular structure of the gadolinium complex of compound **1** (**Gd-1**) and its photo-product **Gd-2**.

as well as a change in the hydration state, since the liberated carboxylate moiety may coordinate to the gadolinium ion replacing one water molecule from the complex. Since it is generally preferred to obtain an increase in signal upon activation, we envision a ratiometric approach, analyzing the T_1 and T_2 relaxation time, for future applications, following the example of Aime *et al.*²⁷

To achieve an efficient, short and high-yielding synthesis, we used a Passerini multicomponent reaction (MCR) for creating the photoactive scaffold²⁸ that could in subsequent transformations be modified with a liposome-anchoring group and a chelator for gadolinium yielding compound **1** (Fig. 3).

The liposomes were prepared with an equimolar mixture of compound **1** and 1,2-dioleoyl-*sn*-glycero-3-phosphocholine (DOPC) in TBS buffer (pH 7.5). By adding Gd(III) to the pre-formed liposomes, we assume to form the complex with the ligands facing to the outside only, resulting in the photo-triggered release of the Gd(III) complex solely to outside and not the lumen. After removal of unselectively bound Gd(III) ions by dialysis, cryoTEM (Fig. S1, ESI[†]), dynamic light scattering analysis (Fig. S7, ESI[†]) and EDX spectroscopy (Fig. S1, ESI[†]) confirmed the formation of small unilamellar vesicles and accumulation of gadolinium in them. The concentration of gadolinium in the sample, determined by ICP-OES, was 0.95 mM, indicating that the complex was formed with 76% of all available ligands, assuming that the complex was only formed with the ligands facing outside.

We further used the FFC NMR relaxometry to confirm the synthetic reproducibility, stability over up to 4 weeks and photoresponsiveness of the liposome formulation (Fig. 4B, C and Fig. S2, ESI[†]). Next, we examined the effect of exposure to light ($\lambda = 400$) nm on the relaxation rate. Irradiation results in a marked decrease in relaxivity within 1 h of irradiation (Fig. 4A). Already after 10 min, a change ΔT_1 of 21% (measured at 10 MHz) was observed, which is comparable to values reported for other light-switchable paramagnetic metal complexes.^{29–31} Moreover, the decrease in relaxivity coincided with a change in the shape of the NMRD profile from the one characteristic for macromolecular or nanoscopic contrast agents with an increase




Fig. 3 Summary of key synthetic steps in the synthesis of compound **1**: Passerini MCR for the synthesis of the photoactive scaffold, an azide-alkyne cycloaddition for attachment of the alkyl chains and a nucleophilic substitution for introduction of the gadolinium ligand.






Fig. 4 Stability and photochemical analysis of the liposomes containing **Gd-1**. (A) Average NMRD profile curves of samples 1–3 before and after irradiation with light ($\lambda = 400$ nm) for indicated times. The results show the average of three measurements of independently prepared samples. (B) The relaxation rates measured at 10 MHz of three independently prepared samples (1–3). The relaxation rate of sample 3 did not change substantially for up to 28 days of storage. (C) Average decrease in relaxivity recorded at 10 MHz compared to decrease in absorbance at $\lambda = 365$ nm.

at higher field strength (> 7 MHz) to the one of a small molecule CA,²⁶ thus indicating the successful uncaging of the gadolinium complex from the liposome. With prolonged irradiation (for 60 min in total), the decrease in relaxivity could be further enhanced to 49% of the initial value (from $10.7 \text{ mM}^{-1} \text{ s}^{-1}$ to $5.2 \text{ mM}^{-1} \text{ s}^{-1}$). Likewise, the relaxation rate at 4.7 T, which is closer to the operating field of (pre-)clinical MRI scanners, decreased by 61% after 60 min irradiation (Fig. S4, ESI†).

Correlation of the kinetics of the relaxivity decrease, measured by FFC relaxometry, and the uncaging process, followed by UV-vis spectroscopy, affirms that the change in relaxivity stems from the photocleavage of compound **Gd-1** docked into the liposomal bilayer (Fig. 4C).

A major concern of the application of Gd-based CAs is the instability of the Gd(III) complex, as free Gd(III) has long-term toxic effects on the human body.³ While cyclic complexes are generally considered to be stable,^{4,32,33} we nevertheless investigated the stability of our Gd(III) complex upon irradiation, employing a photometric assay in which xylenol orange is used as a sensitive indicator for the presence of free Gd(III).³⁴ We found no substantial increase in free Gd(III) concentration after 1 h of irradiation with blue light (Fig. S5, ESI†).

To further validate the applicability of the presented CA in a biological setting, we evaluated the toxicity of the liposome formulation and its photo-products towards human umbilical vein endothelial cells (HUVEC), human normal epithelial cells and M1 macrophages. No cytotoxic effect of liposomes that contained **Gd-1** in their bilayer and that were either kept in the dark or pre-irradiated for up to 60 min, as compared to medium control, were detected on the cell lines (Fig. S8, ESI†).

Next, we explored the possibility of using the liposomal CA for MRI-guided drug delivery. To this end, we evaluated




Fig. 5 Evaluation of the effect of photocleavage on liposome integrity. Fluorescence intensity of 50% DOPC/50% compound **1** liposomes, loaded with calcein at self-quenching concentration (0.1 M), measured as a technical triplicate. Upon irradiation, membrane integrity is reduced as is evident from an increase in fluorescence due to calcein release.

whether cleavage of compound **1** destabilizes the lipid bilayer and thereby promotes the release of the liposome cargo. Calcein, a fluorescent dye, was encapsulated into the aqueous lumen of liposomes decorated with **1** at high, self-quenching concentrations (0.1 M). Only upon irradiation with $\lambda = 400$ nm light, a clear increase in fluorescence was observed (Fig. 5), due to the release and dilution of calcein^{35–37} indicating the destabilization of the bilayer. Unfortunately, it was not possible to determine the exact release rate due to calcein photobleaching.³⁸ DLS showed re-organization of the liposomes, leading to a net decrease in size (Fig. S7, ESI†).

We present here the proof of principle for an activated MRI CA with intrinsic capability for drug delivery, offering prospects for diagnostics and image-guided therapy. We developed and evaluated a light-responsive liposomal gadolinium complex and we demonstrated that its exposure to light results in a marked decrease in relaxation rate, indicating the conversion of a nanoscopic object into a small molecule.

The increase in the permeability of the liposomes upon light exposure opens new possibilities to employ this CA for theranostic applications. To date, there are only few examples of agents combining MR-imaging with pharmacotherapy,^{23,39} including thermo-sensitive release of MRI CA and therapeutics from liposomes and a combination of Gd(III) complexes with porphyrins for PDT.^{40,41} Our strategy, however, stands out due to the prospect of using internal light-emitting targeting moieties for activation, which makes the drug release system unbiased and independent of external stimuli.

In further perspective, we envision to use a two-step approach in which the patient is first injected with a disease-specific antibody (or derivative thereof) equipped with a bioluminescent enzyme–substrate system. After its injection, the conjugate is allowed to selectively accumulate in the lesion(s). Subsequently, the corresponding substrate of the light-producing enzyme is injected and converted at the site of the lesion only, resulting in the localized generation of photons. In turn, these photons locally enhance MRI contrast of the light-activatable CA. Deliberate timing of the scans and stepwise administration of the respective components would result in distinguished resolution. Possible



luminescent tools, that could be used for the activation of the CA, are luciferin/luciferase systems, which have been optimized for *in vivo* bioluminescence imaging^{42,43} or horseradish peroxidase, which has been expressed in mammalian cells and explored for local prodrug activation *in vivo*.⁴⁴ Altogether, this method may be useful to reduce the side effects in systemic chemotherapy for the treatment of localized malignant disease.

For the clinical development of the CA reported here, it is crucial to shift the activation wavelength to >600 nm, to maximize tissue penetration and reduce light-associated toxicity.¹⁸ Recent developments in green and red light-responsive photocaging groups offer efficient activation within a clinical setting.^{45–48} With regards to the use of our system for MRI guided drug delivery, a bathochromic shift in activation wavelength would open up the possibility to use clinically established light delivery systems,^{49–51} commonly used in PDT or photothermal therapies, for triggering the drug release.

The financial support from the Dutch Organization for Scientific Research (VIDI grant no. 723.014.001 for W. S.), the Dutch Cancer Society (grant RUG2014-6986 for W. H.) and the Dutch Ministry of Education, Culture and Science (Gravitation program 024.001.035 for B. L. F.) is gratefully acknowledged. We thank Ms Verena Böhmer for helpful discussions, eng. Theodora D. Tiemersma-Wegman for MS analysis, eng. Hans van der Velde for ICP-OES analysis, Pieter van der Meulen for help with determination of relaxivity at 4.7 T and Mark A. J. M. Hendriks for the macrophages cytotoxicity assay.

Conflicts of interest

The authors declare no conflict of interests.

Notes and references

- 1 D. Hao, T. Ai, F. Goerner, X. Hu, V. M. Runge and M. Tweedle, *J. Magn. Reson. Imaging*, 2012, **36**, 1060–1071.
- 2 J. Lohrke, T. Frenzel, J. Endrikat, F. C. Alves, T. M. Grist, M. Law, J. M. Lee, T. Leiner, K.-C. Li, K. Nikolaou, M. R. Prince, H. H. Schild, J. C. Weinreb, K. Yoshikawa and H. Pietsch, *Adv. Ther.*, 2016, **33**, 1–28.
- 3 J. Garcia, S. Z. Liu and A. Y. Louie, *Philos. Trans. R. Soc., A*, 2017, **375**, 20170180.
- 4 J. Wahsner, E. M. Gale, A. Rodríguez-Rodríguez and P. Caravan, *Chem. Rev.*, 2019, **119**, 957–1057.
- 5 E. Boros, E. M. Gale and P. Caravan, *Dalton Trans.*, 2015, **44**, 4804–4818.
- 6 F. OukhatarkhatMeudal, C. Landon, N. K. Logothetis, C. Platas-Iglesias, G. Angelovski and É. Tóth, *Chem. – Eur. J.*, 2015, **21**, 11226–11237.
- 7 K. Overoye-Chan, S. Koerner, R. J. Looby, A. F. Kolodziej, S. G. Zech, Q. Deng, J. M. Chasse, T. J. McMurphy and P. Caravan, *J. Am. Chem. Soc.*, 2008, **130**, 6025–6039.
- 8 L. Helm, A. E. Merbach and E. Tóth, *The chemistry of contrast agents in medical magnetic resonance imaging*, Wiley, 2nd edn, 2013.
- 9 P. A. Waghorn, C. M. Jones, N. J. Rotile, S. K. Koerner, D. S. Ferreira, H. H. Chen, C. K. Probst, A. M. Tager and P. Caravan, *Angew. Chem., Int. Ed.*, 2017, **56**, 9825–9828.
- 10 D. V. Hingorani, A. S. Bernstein and M. D. Pagel, *Contrast Media Mol. Imaging*, 2015, **10**, 245–265.
- 11 F. A. Rojas-Quijano, G. Tircsó, E. Tircsó, E. Benyó, Z. Baranyai, H. Tran Hoang, F. K. Kálmán, P. K. Gulaka, V. D. Kodibagkar, S. Aime, Z. Kovács and A. D. Sherry, *Chem. – Eur. J.*, 2012, **18**, 9669–9676.
- 12 M. Lepage, W. C. Dow, M. Melchior, Y. You, B. Fingleton, C. C. Quarles, C. Pépin, J. C. Gore, L. M. Matrisian and J. O. McIntyre, *Mol. Imaging*, 2007, **6**, 393–403.
- 13 A. Louie, *J. Magn. Reson. Imaging*, 2013, **38**, 530–539.
- 14 J. Lux and A. D. Sherry, *Curr. Opin. Chem. Biol.*, 2018, **45**, 121–130.
- 15 K. D. Verma, J. O. Massing, S. G. Kamper, C. E. Carney, K. W. MacRenaris, J. P. Basilion and T. J. Meade, *Chem. Sci.*, 2017, **8**, 5764–5768.
- 16 K. W. MacRenaris, Z. Ma, R. L. Krueger, C. E. Carney and T. J. Meade, *Bioconjugate Chem.*, 2016, **27**, 465–473.
- 17 Y. Tang, X. Lu, C. Yin, H. Zhao, W. Hu, X. Hu, Y. Li, Z. Yang, F. Lu, Q. Fan and W. Huang, *Chem. Sci.*, 2019, **10**, 1401–1409.
- 18 R. Weissleder and V. Ntziachristos, *Nat. Med.*, 2003, **9**, 123–128.
- 19 W. A. Velema, W. Szymanski and B. L. Feringa, *J. Am. Chem. Soc.*, 2014, **136**, 2178–2191.
- 20 F. Reefing and W. Szymanski, *Curr. Med. Chem.*, 2018, **24**, 4905–4950.
- 21 C. A. Robertson, D. H. Evans and H. Abrahamse, *J. Photochem. Photobiol., B*, 2009, **96**, 1–8.
- 22 L. Fenno, O. Yizhar and K. Deisseroth, *Annu. Rev. Neurosci.*, 2011, **34**, 389–412.
- 23 F. Reefing and W. Szymanski, *Curr. Opin. Biotechnol.*, 2019, **58**, 9–18.
- 24 P. Caravan, J. J. Ellison, T. J. McMurphy and R. B. Lauffer, *Chem. Rev.*, 1999, **99**, 2293–2352.
- 25 C. S. Bonnet and É. Tóth, *Chim. Int. J. Chem.*, 2016, **70**, 102–108.
- 26 V. Catanzaro, C. V. Gringeri, V. Menchise, S. Padovan, C. Boffa, W. Dastrù, L. Chaabane, G. Digilio and S. Aime, *Angew. Chem., Int. Ed.*, 2013, **52**, 3926–3930.
- 27 S. Aime, F. Fedeli, A. Sanino and E. Terreno, *J. Am. Chem. Soc.*, 2006, **128**, 11326–11327.
- 28 W. Szymański, W. A. Velema and B. L. Feringa, *Angew. Chem., Int. Ed.*, 2014, **53**, 8682–8686.
- 29 C. Tu, E. A. Osborne and A. Y. Louie, *Tetrahedron*, 2009, **65**, 1241–1246.
- 30 C. Tu and A. Y. Louie, *Chem. Commun.*, 2007, 1331.
- 31 G. Heitmann, C. Schütt, J. Gröbner, L. Huber and R. Herges, *Dalton Trans.*, 2016, **45**, 11407–11412.
- 32 P. Hermann, J. Kotek, V. Kubiček and I. Lukeš, *Dalton Trans.*, 2008, 3027.
- 33 T. Kanda, M. Osawa, H. Oba, K. Toyoda, J. Kotoku, T. Haruyama, K. Takeshita and S. Furui, *Radiology*, 2015, **275**, 803–809.
- 34 A. Barge, G. Cravotto, E. Gianolio and F. Fedeli, *Contrast Media Mol. Imaging*, 2006, **1**, 184–188.
- 35 J. N. Weinstein, S. Yoshikami, P. Henkart, R. Blumenthal and W. A. Hagins, *Science*, 1977, **195**, 489–492.
- 36 T. Shimanouchi, P. Walde, J. Gardiner, Y. R. Mahajan, D. Seebach, A. Thoma, S. D. Krämer, M. Voser and R. Kuboi, *Biochim. Biophys. Acta, Biomembr.*, 2007, **1768**, 2726–2736.
- 37 W. Deng, W. Chen, S. Clement, A. Guller, Z. Zhao, A. Engel and E. M. Goldys, *Nat. Commun.*, 2018, **9**, 2713.
- 38 K. E. Roberts, A. K. O'Keeffe, C. J. Lloyd and D. J. Clarke, *J. Fluoresc.*, 2003, **13**, 513–517.
- 39 S. Lacerda and É. Tóth, *ChemMedChem*, 2017, **12**, 883–894.
- 40 A. Sour, S. Jenni, A. Ortí-Suárez, J. Schmitt, V. Heitz, F. Bolze, P. Loureiro de Sousa, C. Po, C. S. Bonnet, A. Pallier, É. Tóth and B. Ventura, *Inorg. Chem.*, 2016, **55**, 4545–4554.
- 41 M. de Smet, S. Langereis, S. van den Bosch and H. Grüll, *J. Controlled Release*, 2010, **143**, 120–127.
- 42 T. Xu, D. Close, W. Handagama, E. Marr, G. Sayler and S. Ripp, *Front. Oncol.*, 2016, **6**, 150.
- 43 D. M. Close, S. S. Patterson, S. Ripp, S. J. Baek, J. Sanseverino and G. S. Sayler, *PLoS One*, 2010, **5**, e12441.
- 44 J. Tupper, M. R. Stratford, S. Hill, G. M. Tozer and G. U. Dachs, *Cancer Gene Ther.*, 2010, **17**, 420–428.
- 45 K. Sitkowska, B. L. Feringa and W. Szymański, *J. Org. Chem.*, 2018, **83**, 1819–1827.
- 46 T. Slanina, P. Shrestha, E. Palao, D. Kand, J. A. Peterson, A. S. Dutton, N. Rubinstein, R. Weinstein, A. H. Winter and P. Klán, *J. Am. Chem. Soc.*, 2017, **139**, 15168–15175.
- 47 X. Wang and J. A. Kalow, *Org. Lett.*, 2018, **20**, 1716–1719.
- 48 N. Rubinstein, P. Liu, E. W. Miller and R. Weinstein, *Chem. Commun.*, 2015, **51**, 6369–6372.
- 49 J. M. Silva, E. Silva and R. L. Reis, *J. Controlled Release*, 2019, **298**, 154–176.
- 50 L. Brancalion and H. Moseley, *Lasers Med. Sci.*, 2002, **17**, 173–186.
- 51 M. A. Calin and S. V. Parasca, *Lasers Med. Sci.*, 2009, **24**, 453–460.

